1. Home
  2. CWD vs VRAX Comparison

CWD vs VRAX Comparison

Compare CWD & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CWD
  • VRAX
  • Stock Information
  • Founded
  • CWD 2009
  • VRAX 2013
  • Country
  • CWD United States
  • VRAX United Kingdom
  • Employees
  • CWD N/A
  • VRAX N/A
  • Industry
  • CWD Real Estate
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • CWD Finance
  • VRAX Health Care
  • Exchange
  • CWD Nasdaq
  • VRAX Nasdaq
  • Market Cap
  • CWD 4.5M
  • VRAX 4.7M
  • IPO Year
  • CWD 2023
  • VRAX 2022
  • Fundamental
  • Price
  • CWD $3.39
  • VRAX $0.91
  • Analyst Decision
  • CWD
  • VRAX Strong Buy
  • Analyst Count
  • CWD 0
  • VRAX 1
  • Target Price
  • CWD N/A
  • VRAX $3.00
  • AVG Volume (30 Days)
  • CWD 23.9K
  • VRAX 55.7K
  • Earning Date
  • CWD 08-11-2025
  • VRAX 02-05-2025
  • Dividend Yield
  • CWD N/A
  • VRAX N/A
  • EPS Growth
  • CWD N/A
  • VRAX N/A
  • EPS
  • CWD N/A
  • VRAX N/A
  • Revenue
  • CWD $35,429,000.00
  • VRAX $6,331.00
  • Revenue This Year
  • CWD N/A
  • VRAX $217,274.83
  • Revenue Next Year
  • CWD $31.12
  • VRAX N/A
  • P/E Ratio
  • CWD N/A
  • VRAX N/A
  • Revenue Growth
  • CWD N/A
  • VRAX N/A
  • 52 Week Low
  • CWD $3.00
  • VRAX $0.74
  • 52 Week High
  • CWD $16.96
  • VRAX $9.00
  • Technical
  • Relative Strength Index (RSI)
  • CWD 48.36
  • VRAX 50.78
  • Support Level
  • CWD $3.13
  • VRAX $0.84
  • Resistance Level
  • CWD $3.75
  • VRAX $0.99
  • Average True Range (ATR)
  • CWD 0.30
  • VRAX 0.07
  • MACD
  • CWD 0.05
  • VRAX 0.02
  • Stochastic Oscillator
  • CWD 53.25
  • VRAX 60.20

About CWD CaliberCos Inc.

CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Share on Social Networks: